Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage i non-small-cell lung cancer

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Zhang, Ting ^a   Yu, Haifeng ^b   Ni, Chao ^c   Zhang, Tao ^a   Liu, Luying ^a   Lv, Qinghua ^a   Zhang, Zhigang ^a   Wang, Zhen ^a   Wu, Dang ^a   Wu, Pin ^a   Chen, Guodi ^a   Wang, Liancong ^a   Wei, Qichun ^a   Huang, Jian ^a   Wang, Xiaojian ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

AGED; B LYMPHOCYTE SUBPOPULATION; CELLULAR IMMUNITY; FEMALE; HUMAN; IMMUNE RECONSTITUTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; NON SMALL CELL LUNG CANCER; PROCEDURES; RADIATION RESPONSE; RADIOSURGERY; T LYMPHOCYTE SUBPOPULATION;

AGED; B-LYMPHOCYTE SUBSETS; CARCINOMA, NON-SMALL-CELL LUNG; CYTOKINES; FEMALE; HUMANS; IMMUNE RECONSTITUTION; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MALE; RADIOSURGERY; T-LYMPHOCYTE SUBSETS;

EID: 85021917145     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-04978-x     Document Type: Article

References (42)

1. Herrera, F. G., Bourhis, J. & Coukos, G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. C. A. Cancer J Clin 67, 65-85 (2017).
2. Orth, M. et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys 53, 1-29 (2014).
3. Jaffray, D. A. Image-guided radiotherapy: from current concept to future perspectives. Nat Rev Clin Oncol 9, 688-99 (2012).
4. Chang, J. Y. et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16, 630-7 (2015).
5. Tepaske, R. et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial. Lancet 358, 696-701 (2001).
6. Barcellos-Hoff, M. H., Park, C. & Wright, E. G. Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer 5, 867-75 (2005).
7. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13, 1050-9 (2007).
8. Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer 15, 409-25 (2015).
9. Frey, B. et al. Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors. Front Immunol 8, 231 (2017).
10. Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589-602 (2013).
11. Matsumura, S. et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181, 3099-107 (2008).
12. De Meerleer, G. et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol 15, e170-7 (2014).
13. Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366, 925-31 (2012).
14. Mole, R. H. Whole body irradiation; radiobiology or medicine? Br J Radiol 26, 234-41 (1953).
15. Wersall, P. J. et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol 45, 493-7 (2006).
16. Ohba, K. et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 43, 575-7 (1998).
17. Kingsley, D. P. An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 48, 863-6 (1975).
18. Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373-7 (2015).
19. Chandra, R. A. et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 4, e1046028 (2015).
20. Golden, E. B. et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16, 795-803 (2015).
21. Ma, C. et al. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Nature 531, 253-7 (2016).
22. Tao, H. et al. Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. Eur J Immunol 45, 999-1009 (2015).
23. Affara, N. I. et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25, 809-21 (2014).
24. Ruhle, P. F., Fietkau, R., Gaipl, U. S. & Frey, B. Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry. Int J Mol Sci 17, 8 (2016).
25. Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-9 (2004).
26. Basu, R. et al. Cytotoxic T Cells Use Mechanical Force to Potentiate Target Cell Killing. Cell 165, 100-10 (2016).
27. Wu, C. Y. et al. Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 20, 644-57 (2014).
28. Anitei, M. G. et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res 20, 1891-9 (2014).
29. Voskoboinik, I., Whisstock, J. C. & Trapani, J. A. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol 15, 388-400 (2015).
30. Thomas, D. A. & Massague, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-80 (2005).
31. Hunder, N. N. et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358, 2698-703 (2008).
32. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-5 (2014).
33. Dudakov, J. A., Hanash, A. M. & van den Brink, M. R. Interleukin-22: immunobiology and pathology. Annu Rev Immunol 33, 747-85 (2015).
34. Mensen, A. et al. Bone marrow T-cell infiltration during acute GVHD is associated with delayed B-cell recovery and function after HSCT. Blood 124, 963-72 (2014).
35. Zhang, S. A. et al. Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. Tumour Biol 39, 10 (2017).
36. van Meir, H. et al. Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. Oncoimmunology 6(2), e1267095 (2016).
37. Dewan, M. Z. et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15, 5379-88 (2009).
38. Schaue, D., Ratikan, J. A., Iwamoto, K. S. & McBride, W. H. Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys 83, 1306-10 (2012).
39. Bernstein, M. B., Krishnan, S., Hodge, J. W. & Chang, J. Y. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol 13, 516-24 (2016).
40. Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589-95 (2009).
41. Kalbasi, A., June, C. H., Haas, N. & Vapiwala, N. Radiation and immunotherapy: a synergistic combination. J Clin Invest 123, 2756-63 (2013).
42. Sarvaria, A. et al. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128, 1346-61 (2016).